Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

Imatinib mesylate (IM) is the standard treatment for advanced, metastatic gastrointestinal stromal tumors (GISTs) and chronic myeloid leukemia (CML) with a fixed daily standard dosage via the oral route. Interindividual and intraindividual variability in plasma concentrations have been closely linke...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Dong, Xiuhua, Wang, QiuJu, Liu, ZhiXi, Dong, XinWei, Shi, Sanjun, Xiao, HongTao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768902/
https://www.ncbi.nlm.nih.gov/pubmed/33381028
http://dx.doi.org/10.3389/fphar.2020.569843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768902/
https://www.ncbi.nlm.nih.gov/pubmed/33381028
http://dx.doi.org/10.3389/fphar.2020.569843

Ejemplares similares